Heron partners with CrossLink to add ~650 sales reps for ZYNRELEF through 2028

HERON THERAPEUTICS, INC. /DE/

CrossLink adds at least 325 sales reps by July 2024 and 650 by Jan 2025.
Fixed-fee per vial compensation based on growth over baseline period.
Up to 1,666,670 shares of common stock and $5M in milestone payments.
Five-year term ending Dec 2028, renewable annually.
Partnership targets orthopedic indications; initial regional rollout expands nationally.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.98

HERON THERAPEUTICS, INC. /DE/ entered into Co-Promotion Agreement with Crosslink Network, LLC valued at Up to 1,666,670 shares of common stock; cash base compensation on fixed-fee per vial basis; up to $5 (effective 2024-01-05).

Action: entry
Agreement: collaboration
Counterparty: Crosslink Network, LLC
Value: Up to 1,666,670 shares of common stock; cash base compensation on fixed-fee per vial basis; up to $5
Effective: 2024-01-05

Exact text from the filing

On January 5, 2024, Heron Therapeutics, Inc. (the “Company”) and Crosslink Network, LLC (“Crosslink”) entered into a Co-Promotion Agreement (the “Co-Promotion Agreement”).

View on SEC.gov

Browse all material agreements →

HERON THERAPEUTICS, INC. /DE/ filing history →

Source: SEC EDGAR

accession 0001193125-24-006600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.